N@N

PSDV, SNGX, RXII, RTIX, RPBC, RGDX, Biomed - Genetics Stocks 14.25% undervalued

^{Published on 2011-01-26 12:41:25 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. PSIVIDA CORP (NASDAQ:PSDV), SOLIGENIX INC (OTCBB:SNGX), RXI PHARMACEUTICALS CORP (NASDAQ:RXII), RTI BIOLOGICS INC (NASDAQ:RTIX), REDPOINT BIO CORP (OTCBB:RPBC), RESPONSE GENETICS INC (NASDAQ:RGDX) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     PSDV       PSIVIDA CORP                        4.5            5.25           14.25% undervalued          Biomed - Genetics      
     SNGX       SOLIGENIX INC                       0.18           0.33           46.00% undervalued          Biomed - Genetics      
     RXII       RXI PHARMACEUTICALS CORP            1.93           4.87           60.40% undervalued          Biomed - Genetics      
     RTIX       RTI BIOLOGICS INC                   2.8            3.77           25.74% undervalued          Biomed - Genetics      
     RPBC       REDPOINT BIO CORP                   0.2            0.31           34.43% undervalued          Biomed - Genetics      
     RGDX       RESPONSE GENETICS INC               2.35           2.38           1.21% undervalued           Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

PSIVIDA CORP (NASDAQ:PSDV) - pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, CODRUG, and Medidur. The companys products include Retisert for the treatment of posterior uveitis; and Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Durasert and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in the United Kingdom and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is based in Watertown, Massachusetts.

SOLIGENIX INC (OTCBB:SNGX) - Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development of products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, as well as biodefense vaccines and therapeutics. The company is developing biotherapeutic products, such as orBec (oral beclomethasone dipropionate) for the treatment and prevention of acute gastrointestinal Graft-versus-Host-Disease, as well as for treatment of chronic GI GVHD; SGX201 for the prevention of acute radiation enteritis; and Lipid Polymer Micelle drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis. Its biodefense product line comprises RiVax, a recombinant subunit vaccine designed to protect against the lethal effects of exposure to ricin toxin; and SGX 202, which is in pre-clinical stage for treating radiation injuries. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix was founded in 1987 and is headquartered in Princeton, New Jersey.

RXI PHARMACEUTICALS CORP (NASDAQ:RXII) - RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including its core focus of developing treatments for anti-scarring and retinal disorders, as well as interest in oncology and indications accessible by spinal cord delivery. RXi Pharmaceuticals Corporation has a joint research agreement with Koninklijke Philips Electronics NV for combining their proprietary technologies for the targeted delivery of experimental therapeutics based on RNA interference (RNAi). The company was formerly known as Argonaut Pharmaceuticals, Inc. and changed its name to RXi Pharmaceuticals Corporation in 2006 before beginning operations in 2007. RXi Pharmaceuticals was founded in 2003 and is based in Worcester, Massachusetts.

RTI BIOLOGICS INC (NASDAQ:RTIX) - RTI Biologics, Inc. and its subsidiaries produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues, and improve surgical outcomes. The company processes human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, fascia lata, pericardium, and sclera and dermal tissues into allografts, as well as bovine animal tissues into xenografts for distribution to hospitals and surgeons. It processes and distributes human and bovine animal tissues for spine, sports medicine, dental, surgical specialties, bone graft substitutes, and general orthopedic markets in the United States and internationally. The company was founded in 1997 and is headquartered in Alachua, Florida.

REDPOINT BIO CORP (OTCBB:RPBC) - Redpoint Bio Corporation engages in the development of healthier foods and beverages, and new approaches for the treatment of diabetes and obesity by understanding of the biology of taste and its relationship to metabolism, satiety, and diabetes. It is developing taste modulators for the food and beverage industry to enhance sweet and savory flavors in food and beverage products, which can lead to reductions in added sugar and salt. The development of healthier and more tasteful food can contribute to enhance the overall health, since various modern diseases are related to excess dietary sugar and salt. The company is based in Ewing, New Jersey.

RESPONSE GENETICS INC (NASDAQ:RGDX) - Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suites for non-small cell lung cancer; ResponseDX: Colon test suites for colorectal cancer; and ResponseDX: Gastric test suites for gastric and gastroesophageal cancer. The companys Response DX test measures the RNA expression of ERCC1, TS, and RRM1 through reverse transcription polymerase chain reaction analysis from a patient's tumor tissue; and polymerase chain reaction analysis of DNA from the patient's sample to determine EGFR amplification, as well as BRAF, EGFR, and KRAS mutational status. It is also developing tests for other types of cancer that identify genetic profiles of tumors that recur after surgery. The company offers its products through its sales force to community based oncologists, hospitals, and physician offices. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net